Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.

Provided herein are methods, compositions, kits, and systems for diagnosing, predicting, and treating gastric cancer for a subject based on the presence and level of antibodies against particular H. pylori proteins in a biological sample obtained from the subject. In particular, provided herein are methods for identifying a subject having increased risk of developing gastric cancer, methods for detecting gastric cancer in a subject, methods for determining an H. pylori antibody signature comprising antibodies, contained in a biological sample from a subject, that specifically bind to immobilized H. pylori antigens, and kits comprising components and instructions for performing the methods of this disclosure.

A fusion protein including a phage tail-spike protein ΦAB6TSP and a signal indicator is provided. Also, a method of detecting bacteria having pseudaminic acid (Pse) is provided, including steps of contacting a sample with a phage tail-spike protein ΦDAB6TSP; and detecting a signal from the sample. The fusion protein and the method of detecting bacteria can be applied to a set of practical diagnosis and therapeutic alternative against Pse-coated antibiotic resistant pathogenic bacteria.

There is provided novel peptides for use in diagnosis of CagA+ H. pylori infection or the prediction of risk for gastric cancer. The peptides bind antibodies from CagA+ H. pylori patients with high specificity and sensitivity, and can be used for example in a diagnostic kit.

Devices and methods for the detection of analytes are disclosed. Devices and methods for detecting food-borne pathogens are disclosed.

Present invention relates to the in vitro use of the level or concentration in a salivary or breath sample of bacteria belonging to the Alloprevotella, Prevotella, Campylobacter, Rothia, Catonella, Porphyromona, Fretibacterium genus, or any combination thereof, for the diagnosis of carcinomas or epidermoid cancers, especially epidermoid cancer of the head and neck, in a patient, or to obtain useful data that allow such a diagnosis.

The purpose of the present invention is to: provide an agent that effectively suppresses inhibition of antigen-antibody reaction in an immunoassay using a sample containing a body fluid, in particular, a component derived from a biological mucosal membrane, such as saliva; and to suppress false positive and false negative results in the immunoassay. The present invention provides an agent for suppressing inhibition of immune reaction, characterized in that the agent comprises a compound of the following (1) or (2): (1) Sulfonic acid compound of the formula R.sup.1—SO.sub.3H or a salt thereof. (In the formula, R.sup.1 is selected from the group consisting of: a straight-chain C.sub.5-C.sub.30 alkyl group; a straight-chain C.sub.1-C.sub.30 alkyl group substituted with an aryl group having at least one straight-chain C.sub.5-C.sub.30 alkyl group; and an aryl group having at least one straight-chain C.sub.5-C.sub.30 alkyl group. These groups may include a substituent group); and (2) Quaternary ammonium ion of the formula N.sup.+—R.sup.2R.sup.3R.sup.4R.sup.5 or a salt thereof. (In the formula, R.sup.2—R.sup.5 are each independently a straight-chain C.sub.1-C.sub.30 alkyl group, or an aryl group substituted with at least one straight-chain C.sub.5-C.sub.30 alkyl group. These groups may include a substituent group); wherein the agent is capable of suppressing immune reaction inhibitory action caused by a body fluid in an immunoassay sample.

Provided are methods and compositions for identifying individuals having intestinal metaplasia (IM) and/or Helicobacter pylori infection based on the levels of antibodies against particular Helicobacter pylori antigens. Patient diagnosis allows for medical interventions, including therapeutic treatments, disease progression preventative measures and enhanced cancer screening. Also provided are methods and compositions for identifying individuals having IM who are at increased risk for developing gastric cancer. Patient diagnosis and stratification by risk allows for targeted screening and monitoring for signs of gastric cancer as well as earlier intervention with cancer preventative treatments.

There is provided novel peptides for use in diagnosis of CagA+ H. pylori infection or the prediction of risk for gastric cancer. The peptides bind antibodies from CagA+ H. pylori patients with high specificity and sensitivity, and can be used for example in a diagnostic kit.

The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Campylobacter species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Campylobacter species in various settings (e.g., food safety, sanitation, modulating microbiome, prebiotics, probiotics).